Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Massachusetts for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Massachusetts only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Massachusetts (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Dana-farber Cancer Institute, Inc. (NPI 1851333686)

Field	Value
Entity Type	Organization
Organization	Dana-farber Cancer Institute, Inc.
Address	450 Brookline Ave
City	Boston
State	MA
ZIP	02215
Taxonomy	General Acute Care Hospital
NPI Enumerated	June 13, 2006

Payer Source	Total Paid
Medicaid	$240.4M
Medicare	$0

Key Findings

This provider reports no Medicare billing on file and $240.4M in lifetime Medicaid revenue, making its public payer footprint effectively single-payer (Medicaid) in the available data. The absence of Medicare claims suggests analyses of Medicare mix or cross‑payer leakage are not possible from these records and that Medicaid payment dynamics will dominate any revenue- or utilization-based conclusions.

Revenue is highly concentrated: the top 3 Medicaid codes by revenue account for 40.2% of the provider's total Medicaid revenue, led by J9271 ($33M, 18.5% of Medicaid revenue), 99212 ($25.4M, 14.3%), and 96413 ($13.2M, 7.4%). This concentration indicates a small set of therapies and visit types drive a large share of payments and should be focal points for contract negotiations and utilization management.

The code mix and volumes strongly indicate an outpatient oncology and infusion-centric operation: high-volume biologic and chemotherapy drug codes such as J9271 (pembrolizumab, 6.2K claims, $5342 avg paid/claim), J9035 (bevacizumab, 6.7K claims, $1316 avg paid/claim), J9299 (nivolumab, 2.8K claims, $3964 avg paid/claim) and infusion/chemotherapy administration codes like 96413 (75.2K claims, $175 avg paid/claim) are dominant. Together these therapies and administration codes are consistent with a large ambulatory cancer-care program that handles both high-cost infusions and high-frequency chemotherapy encounters.

Competitive standing in-state is pronounced for oncology therapeutics: multiple high-cost injectable codes rank #1 among Massachusetts providers and are at the 100th percentile or described as extreme outliers or notably above typical state volume. For example, J9271 ranks #1 of 12 providers (100th percentile; notably above typical state volume for this code) and 96413 ranks #1 of 54 providers (100th percentile; extreme outlier, far above typical state volume), indicating the provider is a dominant statewide source for these oncology services.

Operational throughput is substantial across both visits and diagnostics: 99212 shows 123.4K claims (14.3% of Medicaid revenue) and G0463 shows 149.3K claims, while lab code 80053 has 190.8K claims. These large claim counts for low-to-mid dollar codes imply high ambulatory visit volume and supporting diagnostic services that accompany the high-cost infusion mix.

Financial profile is skewed toward high-cost biologics and supportive-care drugs, which carry high average paid-per-claim amounts and concentrated revenue exposure; examples include J9271 ($5342 avg paid/claim), J9299 ($3964 avg paid/claim), and J2506 ($2199 avg paid/claim). Reliance on a handful of expensive agents means Medicaid spending for this provider is sensitive to changes in drug pricing, biosimilar adoption, and utilization management policies.

The provider has an established presence with an NPI enumerated on 2006-06-13 (~20 years ago), supporting the interpretation that this is a long-standing regional oncology center rather than a recent entrant; tenure combined with the rank and percentile evidence suggests entrenched market position for oncology services in Massachusetts.

Medicaid: Complete Services Breakdown

Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.

357 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	6,180	$5,340	$33M
99212	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a straightforward level of medical decision making,…	123,390	$210	$25.4M
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	75,240	$180	$13.2M
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	5,050	$2,200	$11.1M
J9299	Injection, nivolumab, 1 mg	2,750	$3,960	$10.9M
J9035	Injection, bevacizumab, 10 mg	6,690	$1,320	$8.8M
J2505	Injection, pegfilgrastim, 6 mg	3,900	$2,220	$8.7M
96361	The provider administers intravenous, or IV, fluids with electrolytes through an already established intravenous route for each additional hour to treat more severe dehydration.	21,280	$340	$7.1M
J9355	Injection, trastuzumab, excludes biosimilar, 10 mg	3,380	$1,500	$5.1M
G0463	Hospital outpatient clinic visit for assessment and management of a patient	149,280	$30	$4.6M

Showing 1–10 of 357

Medicaid: Competitive Analysis & Benchmarks

How this provider's Medicaid billing volume and revenue compare to other Massachusetts providers billing the same CPT/HCPCS codes.

Claims Volume vs. Massachusetts Distribution

Dana-farber Cancer Institute, Inc. — 19 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Massachusetts

Full comparison — all codes billed, vs. Massachusetts median

357 rows

CPT/HCPCS Code	Description	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	Injection, pembrolizumab, 1 mg	1	10	210	$5,200	$5.5M
96361	The provider administers intravenous, or IV, fluids with electrolytes through an already established intravenous route for each additional hour to treat more severe dehydration.	18	90	7,560	$350	$4.2M
J9358	Injection, fam-trastuzumab deruxtecan-nxki, 1 mg	1	10	1,250	$2,740	$3.4M
J9299	Injection, nivolumab, 1 mg	1	10	250	$3,570	$3M
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	1	10	590	$1,880	$2.8M
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	2	10	2,050	$1,240	$2.6M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	2	10	1,520	$1,910	$2.6M
J2505	Injection, pegfilgrastim, 6 mg	1	10	650	$1,880	$1.8M
J9306	Injection, pertuzumab, 1 mg	1	10	250	$2,360	$1.6M
J2796	Injection, romiplostim, 10 micrograms	1	10	1,980	$770	$1.5M

Showing 1–10 of 357

Related Providers

Other providers that share a Tax Identification Number (TIN) with Dana-farber Cancer Institute, Inc., ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Jennifer Byer	MA	Medical Oncology Physician	$3.5M	$0
Jochen Lorch	IL	Hematology & Oncology Physician	$1M	$21.7K
Shalini Moningi	OH	Radiation Oncology Physician	$723.2K	$0
Charles Kaufman	MO	Medical Oncology Physician	$501.1K	$0
Daphna Spiegel	MA	Radiation Oncology Physician	$460.8K	$0
John Chi	MA	Neurological Surgery Physician	$444.6K	$0
Monica Krishnan	MA	Radiation Oncology Physician	$340.4K	$0
Theodore Hong	MA	Radiation Oncology Physician	$321.8K	$0
Graeme Steele	MA	Urology Physician	$289.7K	$0
Hasan Zaidi	MA	Neurological Surgery Physician	$279.1K	$0

Nearby Providers

Other providers in the same ZIP code as Dana-farber Cancer Institute, Inc., ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Beth Israel Deaconess Medical Center, Inc.	MA	General Acute Care Hospital	$0	$270.4M
Associated Physicians Of Harvard Medical Faculty Physicians At Beth Is	MA	Emergency Medical Services (Emergency Medicine) Physician	$0	$34.9M
Suburban Home Health Care Inc	MA	Home Health Agency	$0	$23.6M
Fenway Community Health Center, Inc	MA	Federally Qualified Health Center (FQHC)	$0	$22.5M
Atrius Health, Inc.	MA	Internal Medicine Physician	$0	$14.5M
Planned Parenthood League Of Massachusetts, Inc.	MA	Ambulatory Family Planning Facility	$0	$12.8M
Suburban Homemaking & Maternity Agency, Inc.	MA	Home Health Agency	$0	$6.7M
Kids Are People Elementary School	MA	Developmentally Disabled Services Day Training Agency	$0	$6.4M
Avnish Deobhakta	MA	Retina Specialist (Ophthalmology) Physician	$1M	$141.3K
David Meenan	MA	Internal Medicine Physician	$40.4K	$808.1K

Dana-farber Cancer Institute, Inc. — Billing Profile & Reimbursement Data

Sign up for Dana-farber Cancer Institute, Inc. — Billing Profile & Reimbursement Data policy alerts

Dana-farber Cancer Institute, Inc. — Billing Profile & Reimbursement Data

Sign up for Dana-farber Cancer Institute, Inc. — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicaid: Total Revenue Breakdown by CPT/HCPCS Code

Medicaid: Complete Services Breakdown

Medicaid: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References